ALG3 and neoplasm: Treatment with tunicamycin, a broad N-glycosylation inhibitor that affects multiple steps in the pathway, including ALG3-dependent processes, produces effects similar to those of ALG3 deletion, suggesting that general N-glycosylation deficiency can promote ferroptosis-mediated tumor suppression [42,63].